Pharmacotherapy

Do proton pump inhibitors reduce oxaliplatin-induced neuropathy risk?

May 27, 2025

Study details: This retrospective cohort study analyzed data from 1,015 patients undergoing oxaliplatin-based chemotherapy to evaluate whether concomitant use of proton pump inhibitors (PPIs) reduces the incidence of oxaliplatin-induced peripheral neuropathy (OIPN). Patients were divided into PPI and non-PPI groups, and outcomes were assessed using Kaplan–Meier analysis and Cox proportional hazards modeling. Propensity score matching was applied to adjust for baseline demographic differences.

Results: Patients using PPIs had a significantly lower rate of oxaliplatin discontinuation due to OIPN compared with those not using PPIs (p=0.0264). Cox proportional hazards analysis indicated that PPI use was an independent factor associated with reduced discontinuation rates (adjusted hazard ratio (HR), 0.568; 95% confidence interval [CI], 0.344-0.937; p=0.0269). Propensity score matching confirmed these findings, showing a significant reduction in discontinuation rates in the PPI group (p=0.0081).

Clinical impact: Concomitant use of PPIs may be a viable strategy to mitigate OIPN, potentially allowing patients to complete their oxaliplatin-based chemotherapy regimens without dose-limiting neuropathy.

Source:

Mine K, et al. (2025, May 10). Pharmacotherapy. Proton pump inhibitor concomitant use to prevent oxaliplatin-induced peripheral neuropathy: Clinical retrospective cohort study. http://pubmed.ncbi.nlm.nih.gov/40347077/